These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 24206369)

  • 1. Rituximab-related urticarial reaction overlying primary cutaneous follicle centre lymphoma: histological appearance and pathophysiological hypotheses.
    Ingen-Housz-Oro S; Ortonne N; Chosidow O
    J Eur Acad Dermatol Venereol; 2014 Jul; 28(7):976-8. PubMed ID: 24206369
    [No Abstract]   [Full Text] [Related]  

  • 2. Systemic rituximab in multifocal primary cutaneous follicle centre lymphoma.
    Quéreux G; Brocard A; Peuvrel L; Nguyen JM; Knol AC; Dréno B
    Acta Derm Venereol; 2011 Sep; 91(5):562-7. PubMed ID: 21629975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focal rituximab-induced edematous reaction at primary cutaneous follicle center lymphoma lesions: case report and literature review.
    Brunet-Possenti F; Franck N; Tamburini J; Jacobelli S; Avril MF; Dupin N
    Dermatology; 2011; 223(3):200-2. PubMed ID: 21986026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance rituximab should be considered for patients with follicular lymphoma.
    Barr PM
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):541-3. PubMed ID: 25356579
    [No Abstract]   [Full Text] [Related]  

  • 5. A polycyclic annular erythematous plaque on the trunk: a quiz. Annular primary cutaneous follicle centre lymphoma.
    Lemeray J; Guillot B; Dereure O
    Acta Derm Venereol; 2012 Mar; 92(2):221-3. PubMed ID: 22169968
    [No Abstract]   [Full Text] [Related]  

  • 6. Rituximab chemotherapy regimens for treating advanced follicular lymphoma evaluated in new study.
    Askeland G
    Expert Rev Clin Immunol; 2013 May; 9(5):402. PubMed ID: 23772446
    [No Abstract]   [Full Text] [Related]  

  • 7. Rituximab-related urticarial reaction in a patient treated for primary cutaneous B-cell lymphoma.
    Errante D; Bernardi D; Bianco A; De Nardi S; Salvagno L
    Ann Oncol; 2006 Nov; 17(11):1720-1. PubMed ID: 16731537
    [No Abstract]   [Full Text] [Related]  

  • 8. A case of rituximab-related urticarial reaction in cutaneous B-cell lymphoma.
    Rey J; Wickenhauser S; Ivanov V; Coso D; Gastaut JA; Bouabdallah R
    J Eur Acad Dermatol Venereol; 2009 Feb; 23(2):210. PubMed ID: 18482321
    [No Abstract]   [Full Text] [Related]  

  • 9. Severe anemia during rituximab maintenance therapy for follicular lymphoma.
    Liapis K; Harhalakis N; Stefanou G; Apostolidis J
    J Clin Oncol; 2012 Mar; 30(8):e95-6. PubMed ID: 22231048
    [No Abstract]   [Full Text] [Related]  

  • 10. Rapid-onset, prolonged bone marrow failure following rituximab therapy of follicular lymphoma.
    Debatin L; Schmitt-Graeff A; Veelken H
    Onkologie; 2011; 34(6):322-4. PubMed ID: 21625186
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term outcome of intravenous therapy with rituximab in patients with primary cutaneous B-cell lymphomas.
    Brandenburg A; Humme D; Terhorst D; Gellrich S; Sterry W; Beyer M
    Br J Dermatol; 2013 Nov; 169(5):1126-32. PubMed ID: 23796422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab maintenance therapy for follicular lymphoma.
    Zhou H; Zhang B; Zhang J; Ni W; Hu Z
    Lancet; 2011 Apr; 377(9772):1150-1; author reply 1151-2. PubMed ID: 21459204
    [No Abstract]   [Full Text] [Related]  

  • 13. [Subcutaneous Rituximab is effective and safe].
    Häckel A
    Med Monatsschr Pharm; 2014 Jan; 37(1):39-40. PubMed ID: 24490439
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of primary cutaneous follicular centre lymphoma with rituximab: a report of two cases.
    Kennedy GA; Blum R; McCormack C; Prince HM
    Australas J Dermatol; 2004 Feb; 45(1):34-7. PubMed ID: 14961906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uncommon recurrence of follicular lymphoma.
    Austein T; Demme B
    Eur J Haematol; 2012 Jan; 88(1):91. PubMed ID: 21834796
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful treatment of isolated cutaneous relapse of follicular lymphoma with rituximab.
    Ferrer A; López-Guillermo A; Montoto S; Estrach T; Colomo L; Montserrat E
    Ann Hematol; 2001 Aug; 80(8):479-81. PubMed ID: 11563595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of rituximab in follicular lymphoma.
    Johnston KM; Bolbocean C; Connors J; Peacock S
    Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):569-77. PubMed ID: 23140274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
    Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
    Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab by subcutaneous route.
    Solal-Celigny P
    Expert Rev Hematol; 2015 Apr; 8(2):147-53. PubMed ID: 25749209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study.
    Davies A; Merli F; Mihaljevic B; Siritanaratkul N; Solal-Céligny P; Barrett M; Berge C; Bittner B; Boehnke A; McIntyre C; Macdonald D
    Lancet Oncol; 2014 Mar; 15(3):343-52. PubMed ID: 24521993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.